Evidence map›Paper›PMID 41162408›Full record

ArticleNPJ breast cancer2025

Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer.

Jenna Bhimani, Kelli O'Connell, Grace B Gallagher, Victoria S Blinder, Rachael Burganowski, Isaac J Ergas, Jennifer J Griggs, Narre Heon, Sankeerth Jinna, Tatjana Kolevska and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Jenna BhimaniDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kelli O'ConnellDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Grace B GallagherDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Victoria S BlinderDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rachael BurganowskiKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, USA.
Isaac J ErgasDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Jennifer J GriggsDepartment of Medicine, Division of Hematology/Oncology and Department of Health Management and Policy, University of Michigan, Ann Arbor, USA.
Narre HeonDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sankeerth JinnaDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tatjana KolevskaDepartment of Oncology, Kaiser Permanente Medical Center, Vallejo, CA, USA.
Yuriy KotsurovskyyDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Candyce H KroenkeDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Cecile A LaurentDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Raymond LiuDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Kanichi G NakataKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, USA.
Sonia PersaudDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Janise M RohDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Sara TabatabaiDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Emily ValiceDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Peng WangDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elisa V BanderaCancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Erin J Aiello BowlesKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, USA.
Lawrence H KushiDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Elizabeth D KantorDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. kantore@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Risk-based Imaging Strategies to Improve Breast Cancer Surveillance OutcomesP01CA154292 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KARLA M KERLIKOWSKE · 2011 to 2026
$52.9M
CRN4: Cancer Research Resources & Collaboration in Integrated Health Care SystemsU24CA171524 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI KUSHI, LAWRENCE H · 2012 to 2016
$16.0M
Obesity, chemotherapy dosing, and breast cancer outcomesR37CA222793 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KANTOR, ELIZABETH DAVID · 2018 to 2024
$4.0M
Group Health Cancer Research Program Research Specialist AwardR50CA211115 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI BOWLES, ERIN JANELLE AIELLO · 2017 to 2021
$919k
NCI NIH HHS P01 CA154292NCI NIH HHS P30 CA008748NCI NIH HHS R37CA222793NCI NIH HHS R50CA211115NCI NIH HHS U24CA171524
6 · The paper itself

Abstract

Historically, breast cancer patients with obesity have been more likely than normal-weight patients to receive dose-reduced chemotherapy, although contemporary dosing practices of patients with obesity remain unclear. Among 9708 women treated with adjuvant chemotherapy for stage I-IIIA breast cancer at two integrated healthcare delivery systems (2005-2019), we used generalized linear models to estimate adjusted prevalence ratios between body mass index (BMI) and comorbidity and chemotherapy dosing (first cycle dose reduction (FCDR), dose proportion < 90%) and average relative dose intensity (ARDI) < 90%). A strong, independent association was observed between BMI and FCDR (PR

Identifiers

PMID41162408
PMCPMC12572154

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.